Essential thrombocythemia and primary myelofibrosis:

Description Percentage

Requiring either continuous myelosuppressive therapy or, for six months following hospital admission, peripheral blood or bone marrow stem cell transplant, or chemotherapy, or interferon treatment

100
Description Percentage

Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count <500 x 10  9\L

70
Description Percentage

Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count of 200,000-400,000, or white blood cell (WBC) count of 4,000-10,000

30
Description Percentage

Asymptomatic

0

Note (1): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703.

Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant; or during the period of treatment with chemotherapy (including myelosuppressants). Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.

Need help with Medical Compensation? If your disability claim is not clearly supported by your medical records along with evidence, your claim can be denied. We have helped thousands of Veterans claim the compensation they deserve.

Get More Info